QuidelOrtho Corporation (NASDAQ: QDEL) Securities Class Action: The litigation is focused on the propriety of QuidelOrtho's past assurances about its preparedness to maintain a stable high margin revenue stream from its respiratory business in the face of the COVID-19 pandemic becoming an endemic and about its FDA submission for its purported "next flagship product" (the "Savanna RVP4 Test") being "on track." On Apr. 2, 2024, the price of QuidelOrtho shares fell $4.85 (10%) after the company announced that ...